Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain

Regina Juanbeltz, Alejandra Pérez-García, Aitziber Aguinaga, Iván Martínez-Baz, Itziar Casado, Cristina Burgui, Silvia Goñi-Esarte, Jesús Repáraz, José Manuel Zozaya, Ramón San Miguel, Carmen Ezpeleta, Jesús Castilla, EIPT-VHC Study Group, Regina Juanbeltz, Alejandra Pérez-García, Aitziber Aguinaga, Iván Martínez-Baz, Itziar Casado, Cristina Burgui, Silvia Goñi-Esarte, Jesús Repáraz, José Manuel Zozaya, Ramón San Miguel, Carmen Ezpeleta, Jesús Castilla, EIPT-VHC Study Group

Abstract

Background: The World Health Organization set targets to eliminate hepatitis C virus (HCV) infection through detection and treatment of all cases by 2030. This study aimed to describe the progress and difficulties in the elimination of HCV infection in Navarra, Spain.

Methods: Using electronic healthcare databases, we performed a population-based prospective cohort study to describe changes in the prevalence of diagnosed active HCV infection at the beginning of 2015 and the end of 2017, the rate of new diagnoses and the rate of post-treatment viral clearance (PTVC) during this period.

Results: At the beginning of 2015 there were 1503 patients diagnosed with positive HCV-RNA, 2.4 per 1000 inhabitants, and at the end of 2017 the prevalence had decreased by 47%. In the study period, 333 (18 per 100,000 person-years) new positive HCV-RNA cases were detected, but only 76 (23%; 4.2 per 100,000 person-years) did not have anti-HCV antibodies previously detected. Prevalent cases and new diagnoses of active infection were more frequent in men, people born in 1950-1979, HIV-infected patients and in those with lower income levels. Among patients with HCV-RNA, 984 achieved PTVC (22.7 per 100 person-years). PTVC was less frequent in patients born before 1940, in immigrants and in patients with lower income levels.

Conclusions: The prevalence of diagnosed active HCV infection has dropped by almost half over three years, because the number of patients with PTVC was much higher than the number of new diagnoses. Interventions specifically targeted at population groups with less favourable trends may be necessary.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Input and output flows in…
Fig 1. Input and output flows in the population-based cohort study, Navarra, Spain, 2015–2017.

References

    1. European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017;2:325–36.
    1. Domínguez A, Bruguera M, Vidal J, Plans P, Salleras L. Community-based sero-epidemiological survey of HCV infection in Catalonia, Spain. J Med Virol 2001;65:688–93.
    1. Bruguera M, Forns X. Hepatitis C in Spain (In Spanish). Med Clin (Barc) 2006;127:113–7.
    1. Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014;21(Suppl 1):5–33.
    1. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. April 2014. Available at:
    1. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385:1124–35.
    1. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–93.
    1. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594–603.
    1. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127–35.
    1. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973–82.
    1. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspective. Liver Int 2016;36 Suppl 1:47–57.
    1. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. June 2016. Geneva:
    1. Hellard M, Sacks-Davis R, Doyle J. Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks. J Epidemiol Community Health 2016. pii: jech-2015-205454.
    1. Gelson W, Alexander G. Is elimination of hepatitis C from the UK by 2030 a realistic goal? Br Med Bull. 2017;123(1):59–67.
    1. Ministerio de Sanidad, Servicios Sociales e Igualdad. Plan estratégico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad, 21 de mayo de 2015. Available at:
    1. Aguinaga A, Díaz-González J, Pérez-García A, Barrado L, Martínez-Baz I, Casado I, et al. The prevalence of diagnosed and undiagnosed hepatitis C virus infection in Navarra, Spain, 2014–2016 (In Spanish). Enferm Infecc Microbiol Clin 2018;36:325–31.
    1. Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, et al. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat 2018;25 Suppl 1:6–17.
    1. Lazarus JV, Wiktor S, Colombo M, Thursz M; EASL International Liver Foundation. Micro-elimination—A path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665–6.
    1. Caro-Murillo A, Moreno-Iribas C, Irisarri F, Aldaz P, Napal V, Valera-Santos C, et al. Evaluation of the surveillance system for human immunodeficiency virus infections of Navarra, Spain, 1985–2003 (In Spanish). Rev Esp Salud Pública 2007;81:387–9.
    1. European Association for the Study of the Liver. EASL Recommendations on treatment of hepatitis C 2015. J Hepatol 2015;63:199–236.
    1. Castilla J, Pollán M, López-Abente G. The AIDS epidemic among Spanish drug users: A birth-cohort associated phenomenon. Am J Public Health1997;87:770–4.
    1. García Comas L, Ordobás Gavín M, Sanz Moreno JC, Ramos Blázquez B, Gutiérrez Rodríguez A, Astray Mochales J, et al. Prevalence of hepatitis C antibodies in the population aged 16–80 years in the Community of Madrid 2008–2009. J Med Virol 2015;87:1697–701.
    1. Garriga C, Manzanares-Laya S, García de Olalla P, Gorrindo P, Lens S, Solà R, et al. Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns. PLoS One 2017;12(11):e0187893
    1. Richard JL, Schaetti C, Basler S, Mäusezahl M. The epidemiology of hepatitis C in Switzerland: trends in notifications, 1988–2015. Swiss Med Wkly 2018;148:w14619
    1. Bolotin S, Feld JJ, Garber G, Wong WWL, Guerra FM, Mazzulli T. Population-based estimate of hepatitis C virus prevalence in Ontario, Canada. PLoS One 2018;13(1):e0191184
    1. Lazarus JV, Bromberg DJ, Del Amo J, Norgaard O, García-Samaniego J, Casellas A, et al. Hepatitis C prevalence among the immigrant population in Spain: A systematic review and meta-analysis. Enferm Infecc Microbiol Clin 2018. pii: S0213-005X(18)30171-X.
    1. Janjua NZ, Islam N, Wong J, Yoshida EM, Ramji A, Samji H, et al. Shift in disparities in Hepatitis C treatment from interferon to DAA era: A population-based cohort study. J Viral Hepatol 2017;24:624–30.
    1. Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, et al. Disparities in direct acting antivirals uptake in HIV‐hepatitis C co‐infected populations in Canada. J Int AIDS Soc 2017; 20(3):e25013
    1. Marcus JL, Hurley LB, Chamberland S, Champsi JH, Gittleman LC, Korn DG, et al. Disparities in initiation of direct-acting antiviral agents for hepatitis C virus infection in an insured population. Public Health Rep 2018;133:452–60.
    1. Younossi ZM, Bacon BR, Dieterich DT, Flamm SL, Kowdley K, Milligan S, et al. Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network. J Viral Hepat 2016;23:447–54.
    1. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006;13:34–41.
    1. Juanbeltz R, Zozaya JM, Repáraz J, Castilla J, Sarobe MT, Úriz Orano JI, et al. Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C (In Spanish). An Sist Sanit Navar 2017;40:57–66. doi:

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren